A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to determine whether CCX282-B is effective in treating patients with moderate to severe Crohn's Disease.
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.
Key Inclusion Criteria:
Key Exclusion Criteria:
Centro Petrópolis, 25620-040, Brazil
České Budejovice, Czechia
Arhus C, 8000, Denmark
Berlin, Germany
Trzifin, Israel
Szczecin, 71-252, Poland